A Phase 2/3 interventional study of Oxycodone and Naloxone in Malignant Pain and Non-malignant Pain, sponsored by Mundipharma Research GmbH & Co KG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by Mundipharma Research GmbH & Co KG (part of Mundipharma) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany — 7 open to participants now, 12 under way, 4 of them phase 3. Bronchiolitis Obliterans Syndrome · Germany.
Among the 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany, this one is the 31st largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2014, is one of 3 in phase 2/3, and was the 29th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →7 of the 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Germany, United States, Belgium and 3 more countries
Ages 2–17
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 14 more countries
Ages 1–18
Sanofi · Sites in Germany, United States, Belgium and 10 more countries
Ages 1–18
Incyte Corporation · Sites in Germany, United States, Australia and 10 more countries
Ages 12+
IRCCS Sacro Cuore Don Calabria di Negrar · Sites in Germany, Belgium, Italy and 2 more countries
Ages 5+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 26 · Phase 3 25 · Phase 4 3
First in 2003; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 173 across the 56 interventional studies, 203 across the 6 observational. Of the 45 that completed or were terminated, 34 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 62 have an industry lead sponsor. The 10 most frequent:
This study is registered under Mundipharma Research GmbH & Co KG, one of the names counted as Mundipharma. Under that name alone:
Mundipharma Research GmbH & Co KG is the lead sponsor of 16 studies on the registry; none are open to participants now.
Mundipharma has 3 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Bronchiolitis Obliterans Syndrome with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06873308IRCCS Sacro Cuore Don Calabria di NegrarAssessment of Infection Activity in Travelers and Migrants Diagnosed With Chronic Schistosomiasis | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 62 studies in Bronchiolitis Obliterans Syndrome with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is aimed to demonstrate equivalence between combinations of lower strength OXN PR tablets (OXN PR LST) and single higher strength OXN PR tablets (OXN PR HST) taken at the same overall daily dose.
Study OXN3508 is a multicenter double-blind, double-dummy, randomised, cross-over, 2-period, phase III study in male and female subjects with severe non-malignant or malignant pain that requires around-the-clock opioid therapy at a daily dose of 120/60 mg or 160/80 mg oxycodone/naloxone prolonged release (OXN PR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Prolonged release oxycodone/naloxone higher strength tablets
Drug: Oxycodone
Prolonged release oxycodone/naloxone lower strength tablets
Drug: Naloxone
(mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale.)
Pain scores based on the mean of subjects average pain over the last 24 hours as assessed by the pain intensity scale. To demonstrate equivalence between multiple lower strength OXN PR tablets and a single higher strength OXN PR tablet taken at the same overall total daily dose
Time frame: 24 hours at one day in week 2, 3 5 and 6 from date of randomisation.
Equivalent bowel function as assessed by the Bowel Function Index (BFI).
Time frame: Week 2, 3 5 and 6 from date of randomisation.
Pain scores of subjects average pain over the last 24 hours and rescue medication use.
Time frame: Week 1,2,3,4,5 and 6 from date of randomisation
To assess bowel function (assess BFI and laxative use)
To assess BFI and laxative use
Time frame: Week 1,2,3,4,5 and 6 from date of randomisation
To assess quality of life based on the EuroQol EQ-5D.
EuroQol EQ-5D is a standardized instrument for use as a measure of health outcome.
Time frame: Visit 3 and visit 6 from date of randomisation
Number of participants with adverse events, high/low laboratory values and clinically significant ECG findings.
Time frame: Up to 35 weeks
Pain right now scores at intake of oxycodone/naloxone tablets.
Time frame: Week 2,3,5 and 6 from date of randomisation
The record gives a start of Nov 2014, a primary completion of Mar 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
Bronchiolitis Obliterans Syndrome →
Mundipharma Research GmbH & Co KG →